Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Growth From $105.59 Billion In 2026 To $133.49 Billion By 2030 At A CAGR Of 6%
The bioinformatics in in-vitro diagnostics (ivd) testing market size has experienced strong growth over recent years. It is anticipated to increase from $98.89 billion in 2025 to $105.59 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be attributed to several factors, including the rising volumes of molecular diagnostic testing, the expanded integration of next-generation sequencing in diagnostics, the development of centralized diagnostic laboratories, the availability of advanced diagnostic hardware, and the increasing utilization of data-driven clinical decision support.
The bioinformatics in in-vitro diagnostics (IVD) testing market is projected to experience substantial growth over the coming years. This market is anticipated to reach $133.49 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.0%. Factors contributing to this growth during the forecast period include the escalating demand for precise diagnostics, the broadened scope of personalized medicine diagnostics, increased investments in AI-powered diagnostic platforms, the expanding utilization of cloud-based diagnostic analytics, and greater regulatory approval for digital diagnostics. Key trends expected within this period encompass the increased application of AI-driven diagnostic interpretation software, the surging adoption of cloud-enabled IVD bioinformatics platforms, the deepening integration of molecular and clinical data sets, the proliferation of companion diagnostics analytics, and an intensified emphasis on processing diagnostic data in real-time.
Get A Free Sample Report With In-Depth Market Insights:
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Growth Catalysts And Demand Drivers
The rising incidence of cancer is anticipated to boost the expansion of bioinformatics within the IVD testing market moving ahead. Cancer broadly refers to a collection of illnesses marked by uncontrolled cell proliferation capable of invading and metastasizing to other areas of the body. The growing occurrence of cancer stems from diverse elements linked to exposure, lifestyle choices, and environmental impacts. In IVD testing, bioinformatics revolutionizes cancer diagnostics by offering accurate, tailored, and exhaustive genetic information, which improves early identification, informs treatment choices, and betters patient results. For example, in February 2024, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported a forecast of over 35 million new cancer cases by 2050. Consequently, the escalating prevalence of cancer is a key driver for bioinformatics in the IVD testing market.
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Segment Breakdown: Which Categories Lead On Revenue?
The bioinformatics in in-vitro diagnostics (ivd) testing market covered in this report is segmented –
1) By Component: Hardware, Software
2) By Type Of Test: Blood Based Tests, Tissue Based Tests
3) By Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications
Subsegments:
1) By Hardware: Analyzers, Laboratory Equipment, Data Storage Devices, Sensors And Detectors, Workstations And Data Processing Hardware
2) By Software: Bioinformatics Platforms, Data Management and Integration Software, Analytics And Interpretation Software, Cloud-Based Software Solutions, AI-Based Software For Diagnostics
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Trends Shaping Long-Term Demand
Leading companies in the bioinformatics in the IVD testing market are concentrating on developing innovative solutions, such as next-generation sequencing (NGS) technology. These efforts aim to improve the detection and analysis of genetic mutations, enhance diagnostic accuracy, and facilitate personalized medicine approaches. Next-generation sequencing (NGS) itself is a high-throughput technology designed for the rapid sequencing of entire genomes or specific DNA and RNA regions, thereby enabling comprehensive genetic analysis. For instance, in January 2024, QIAGEN Digital Insights, the bioinformatics division of the Netherlands-based molecular diagnostics company QIAGEN, introduced LightSpeed. This ultra-fast NGS secondary-analysis software accelerator is integrated into its CLC Genomics Workbench Premium platform. The LightSpeed module allows laboratories to process somatic cancer NGS data at unprecedented speed, converting raw sequencing files (FASTQ) into variant calls (VCF) in mere minutes, while also reducing the cost per sample. LightSpeed supports high-throughput cancer panels and is compatible with both cloud-based and on-premises workflows, which empowers bioinformatics teams to quickly analyze multiple tumor genes and biomarkers from a single sample to guide precision oncology decision-making.
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Leading Players And Competitive Positioning
Major companies operating in the bioinformatics in in-vitro diagnostics (ivd) testing market are Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN N.V, Agilent Technologies Inc, PerkinElmer Inc, Roche Holding AG, BGI Genomics Co Ltd, DNAnexus Inc, Seven Bridges Genomics Inc, Dassault Systèmes SE (BIOVIA), Genedata AG, Partek Inc, Data4Cure Inc, Ontoforce NV, Geneious (Biomatters), SoftGenetics LLC, Eagle Genomics Ltd, Wuxi NextCODE Genomics, Bio‑Rad Laboratories Inc, Eurofins Scientific SE
View The Full Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report:
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (ivd) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









